<DOC>
	<DOC>NCT00357279</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety and effectiveness of a one dose strength of denufosol compared to placebo in patients with mild CF lung disease.</brief_summary>
	<brief_title>Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Have confirmed diagnosis of cystic fibrosis Have FEV1 of greater than or equal to 75% of predicted normal for age, gender, and height Be able to reproducibly perform spirometry maneuvers Be clinically stable for at least 4 weeks prior to screening Have abnormal renal or liver function Have chest xray at screening suggesting clinically significant active pulmonary disease Be colonized with Burkholderia cepacia Have had a lung transplant</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>